R&D at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's R&D?
- Cytokinetics (CYTK) reported R&D of $95.53M in Q1 2026.
- How has Cytokinetics's R&D changed year-over-year?
- Cytokinetics's R&D decreased by 2.8% year-over-year, from $98.26M to $95.53M.
- What is the long-term trend for Cytokinetics's R&D?
- Over 4 years (2021 to 2025), Cytokinetics's R&D has grown at a 26.9% compound annual growth rate (CAGR), from $159.94M to $414.45M.
- What does R&D mean?
- The costs associated with creating new products or improving existing ones.
- How do you interpret R&D?
- Higher spending reflects a commitment to innovation and pipeline expansion, though it directly reduces current profitability.
- How does R&D compare across companies?
- High R&D intensity is typical for pre-commercial biotech companies compared to mature pharmaceutical firms.